Bristol Myers Squibb Company is in a race against the clock as multiple blockbusters – including top-sellers Eliquis (apixaban) and Opdivo (nivolumab) – face losses of exclusivity over the next five years. The big pharma has nine new products that are expected to generate a combined $25bn-plus in sales by 2030 and six drug candidates in registrational trials that could add another $10bn or more in peak sales. And now the company will move another six programs into registrational trials during the next 18 months.
Key Takeaways
-
BMS is preparing for five products that altogether generated $27.8bn in 2022 sales to lose patent exclusivity between 2024 and 2028.
-
The company believes its nine new launches will produce $25bn-plus in sales by 2030 and six next wave launches will produce more than $10bn in peak sales
Bristol revealed its plans to advance those assets into later-stage clinical trials on 14 September when it hosted an R&D day event to discuss its renewed approach to drug discovery and development, with a focus on moving therapeutic candidates through the pipeline more quickly and efficiently